Boulytcheva I V, Kushlinskii N E, Dvorova E K, Kazachok I V, Makhson A N
Department of Pathological Anatomy, Moscow Oncological Hospital No. 62, Moscow, Russia.
Bull Exp Biol Med. 2010 Sep;149(3):341-6. doi: 10.1007/s10517-010-0942-z.
The expression of MMP-1, -2, -9 and TIMP-1 was studied in 10 benign cartilage-forming osteal tumors (5 osteochondromas and 5 chondromas) and 39 chondrosarcomas (14 central, 4 periosteal, 7 dedifferentiated, and 14 secondary tumors). No expression of MMP and TIMP-1 was detected in benign cartilage-forming osteal tumors. In chondrosarcomas, the expression of MMP-1 was detected in 84.6%, of MMP-2 in 71.8, of MMP-9 in 97.4, and of TIMP-1 in 82.4% cases, the levels of expression of these markers varied from 10 to 60%. The expression of MMP-1 was not associated with patient gender, maximum size and degree of differentiation of the tumor, but was linked with age. The expression of MMP-1 was more often detected in central and dedifferentiated chondrosarcomas; the expression of MMP-1(+) was significantly associated with 3-year relapse-free and 5-year overall survival of the patients. The expression of MMP-1 in the tumor was associated with unfavorable course of the disease. The values of MMP-2 expression in chondrosarcomas did not reflect the main clinical morphological characteristics of the disease and its prognosis. The level of MMP-9 protein expression in chondrosarcomas ≥40% is prognostically unfavorable, while <40% is a favorable factor for 3-year relapse-free survival. The risk of disease relapse within 1 year after the beginning of therapy was maximum in T3 tumors with expression of MMP-9 protein ≥40%. No relationships between the parameters of TIMP-1 expression in chondrosarcomas and the main clinical morphological characteristics of the disease and its prognosis were detected.
在10例良性软骨形成性骨肿瘤（5例骨软骨瘤和5例软骨瘤）和39例软骨肉瘤（14例中央型、4例骨膜型、7例去分化型和14例继发性肿瘤）中研究了基质金属蛋白酶-1（MMP-1）、-2、-9和金属蛋白酶组织抑制因子-1（TIMP-1）的表达情况。在良性软骨形成性骨肿瘤中未检测到MMP和TIMP-1的表达。在软骨肉瘤中，84.6%的病例检测到MMP-1表达，71.8%检测到MMP-2表达，97.4%检测到MMP-9表达，82.4%检测到TIMP-1表达，这些标志物的表达水平在10%至60%之间。MMP-1的表达与患者性别、肿瘤最大尺寸和分化程度无关，但与年龄有关。MMP-1的表达在中央型和去分化型软骨肉瘤中更常被检测到；MMP-1（+）的表达与患者3年无复发生存率和5年总生存率显著相关。肿瘤中MMP-1的表达与疾病的不良病程相关。软骨肉瘤中MMP-2的表达值不能反映疾病的主要临床形态学特征及其预后。软骨肉瘤中MMP-9蛋白表达水平≥40%在预后方面不利，而<40%是3年无复发生存的有利因素。治疗开始后1年内疾病复发风险在MMP-9蛋白表达≥40%的T3肿瘤中最高。未检测到软骨肉瘤中TIMP-1表达参数与疾病的主要临床形态学特征及其预后之间的关系。
